NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference

Rhea-AI Summary

NetraMark Holdings (OTCQB: AINMF), an AI company focused on clinical trials transformation, announced its CEO George Achilleos will attend Canaccord Genuity's 45th Annual Growth Conference from August 12-14, 2025, in Boston, Massachusetts.

The company's platform, NetraAI, is designed to enhance clinical development by identifying explainable patient subpopulations, uncovering drug response drivers, reducing placebo effects, and improving patient selection strategies. During the conference, the CEO will be available for one-on-one meetings with institutional investors, pharmaceutical sponsors, and strategic partners to discuss the platform's applications across therapeutic areas.

TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials is pleased to announce that its Chief Executive Officer, George Achilleos, will be attending the 45th Annual Growth Conference hosted by Canaccord Genuity, taking place August 12–14, 2025, in Boston, Massachusetts.

This event brings together innovative and disruptive growth companies across multiple sectors with institutional investors from around the globe. The conference is recognized as a venue for networking, strategic collaboration, and showcasing novel technology platforms.

NetraMark seeks to transform clinical development through its mathematically-augmented AI platform, NetraAI. Purpose-built to extract clinically relevant insights from complex and noisy datasets, NetraAI seeks to identify explainable patient subpopulations that may enable trial sponsors to uncover drug response drivers, mitigate placebo effects, and improve patient selection strategies. The approach is intended to help de-risk late-phase trials, improve signal detection, and accelerate development timelines.

George Achilleos will be available for one-on-one meetings during the conference to engage with institutional investors, pharmaceutical sponsors, and strategic partners. These meetings will provide an opportunity to discuss how NetraMark’s explainable AI platform is being applied across therapeutic areas to improve trial outcomes and support precision medicine strategies.

About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

For more NetraMark information, see the company’s website and follow NetraMark on LinkedIn.

Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding NetraMark’s work to advance the transformation of clinical development through its AI platform, the intended capabilities of NetraAI to identify explainable patient subpopulations and enable trial sponsors to uncover drug response drivers, mitigate placebo effects, and improve patient selection strategies, the potential for NetraAI to support late-phase trials, improve signal detection, and accelerate development timelines, and the application of NetraAI across therapeutic areas to support trial outcomes and precision medicine strategies, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549

FAQ

When and where is NetraMark (AINMF) presenting at the Canaccord Genuity Conference?

NetraMark will attend the conference from August 12-14, 2025 in Boston, Massachusetts.

What is NetraMark's (AINMF) NetraAI platform used for in clinical trials?

NetraAI is designed to identify patient subpopulations, uncover drug response drivers, mitigate placebo effects, and improve patient selection strategies in clinical trials.

Who will represent NetraMark (AINMF) at the Canaccord Genuity Conference?

George Achilleos, NetraMark's Chief Executive Officer, will represent the company and be available for one-on-one meetings.

What type of meetings will NetraMark (AINMF) conduct at the conference?

NetraMark will conduct one-on-one meetings with institutional investors, pharmaceutical sponsors, and strategic partners to discuss their AI platform's applications.